150 related articles for article (PubMed ID: 35923563)
41. A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin.
Ge Y; Zhang W; Qin J; Zhang C; Tian W; Zhang Q; Shao J; Li S; Fang L; Zheng J
Med Oncol; 2019 Oct; 36(12):96. PubMed ID: 31659495
[TBL] [Abstract][Full Text] [Related]
42. Differential transformation of primary human embryo retinal cells by adenovirus E1 regions and combinations of E1A + ras.
Byrd PJ; Grand RJ; Gallimore PH
Oncogene; 1988 May; 2(5):477-84. PubMed ID: 2967455
[TBL] [Abstract][Full Text] [Related]
43. The Ras-ERK signaling pathway regulates acetylated activating transcription factor 2 via p300 in pancreatic cancer cells.
Li M; Song SW; Ge Y; Jin JY; Li XY; Tan XD
Ann Transl Med; 2020 Oct; 8(19):1234. PubMed ID: 33178766
[TBL] [Abstract][Full Text] [Related]
44. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
45. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation.
Deschênes-Simard X; Gaumont-Leclerc MF; Bourdeau V; Lessard F; Moiseeva O; Forest V; Igelmann S; Mallette FA; Saba-El-Leil MK; Meloche S; Saad F; Mes-Masson AM; Ferbeyre G
Genes Dev; 2013 Apr; 27(8):900-15. PubMed ID: 23599344
[TBL] [Abstract][Full Text] [Related]
46. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A.
Giordano A; Lee JH; Scheppler JA; Herrmann C; Harlow E; Deuschle U; Beach D; Franza BR
Science; 1991 Sep; 253(5025):1271-5. PubMed ID: 1653969
[TBL] [Abstract][Full Text] [Related]
47. p21Waf1 deficiency does not decrease DNA repair in E1A+cHa-Ras transformed cells by HDI sodium butyrate.
Igotti M; Gnedina O; Morshneva A; Svetlikova S; Pospelov V
Biol Chem; 2018 Oct; 399(11):1297-1304. PubMed ID: 30044758
[TBL] [Abstract][Full Text] [Related]
48. [The p21(WAF1) cyclin-kinase inhibitor: in vivo interaction with E1A adenoviral Ad2 and Ad12 oncoproteins].
Timofeev OV; Pospelov VA
Tsitologiia; 2003; 45(11):1109-18. PubMed ID: 14989150
[TBL] [Abstract][Full Text] [Related]
49. [Anti-apoptotic and antiproliferative effect of bcl-2 gene transferred to E1A+cHa-ras-transformed cells].
Tararova ND; Bulavin DV; Neliudova AM; Aksenov ND; Pospelov VA; Pospelova TV
Tsitologiia; 2002; 44(5):441-9. PubMed ID: 14696253
[TBL] [Abstract][Full Text] [Related]
50. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells.
Plattner R; Gupta S; Khosravi-Far R; Sato KY; Perucho M; Der CJ; Stanbridge EJ
Oncogene; 1999 Mar; 18(10):1807-17. PubMed ID: 10086335
[TBL] [Abstract][Full Text] [Related]
51. A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer.
Fang L; Cheng Q; Zhao J; Ge Y; Zhu Q; Zhao M; Zhang J; Zhang Q; Li L; Liu J; Zheng J
Oncotarget; 2016 Jul; 7(30):48309-48320. PubMed ID: 27340782
[TBL] [Abstract][Full Text] [Related]
52. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
53. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
54. Opposing roles of Ras/Raf oncogenes and the MEK1/ERK signaling module in regulation of expression and adhesive function of surface transglutaminase.
Akimov SS; Belkin AM
J Biol Chem; 2003 Sep; 278(37):35609-19. PubMed ID: 12832399
[TBL] [Abstract][Full Text] [Related]
55. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
56. Protein kinase A balances the growth factor-induced Ras/ERK signaling.
Pursiheimo JP; Kieksi A; Jalkanen M; Salmivirta M
FEBS Lett; 2002 Jun; 521(1-3):157-64. PubMed ID: 12067709
[TBL] [Abstract][Full Text] [Related]
57. E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2.
Akli S; Zhan S; Abdellatif M; Schneider MD
Circ Res; 1999 Aug; 85(4):319-28. PubMed ID: 10455060
[TBL] [Abstract][Full Text] [Related]
58. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
[TBL] [Abstract][Full Text] [Related]
59. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
60. Sprouty is a cytoplasmic target of adenoviral E1A oncoproteins to regulate the receptor tyrosine kinase signalling pathway.
Zaremba A; Schmuecker U; Esche H
Virol J; 2011 Apr; 8():192. PubMed ID: 21518456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
